{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:30:56Z","timestamp":1791552656786,"version":"4.3.4"},"reference-count":167,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01956","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:31:11Z","timestamp":1598315471000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":240,"title":["Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment"],"prefix":"10.3389","volume":"11","author":[{"given":"Yuxiao","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5245034","DOI":"10.1155\/2019\/5245034","article-title":"Combinatorial approach to improve cancer immunotherapy: rational drug design strategy to simultaneously hit multiple targets to kill tumor cells and to activate the immune system","volume":"2019","author":"Joshi","year":"2019","journal-title":"J Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s13402-019-00456-w","article-title":"Recent advances in the clinical development of immune checkpoint blockade therapy","volume":"42","author":"Ghahremanloo","year":"2019","journal-title":"Cell Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/CCO.0000000000000466","article-title":"Immunotherapy-based combinations: an update","volume":"30","author":"Fuc\u00e0","year":"2018","journal-title":"Curr Opin Oncol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12079-017-0433-3","article-title":"Integration of pro-and anti-angiogenic signals by endothelial cells","volume":"12","author":"Kazerounian","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.3389\/fimmu.2018.03081","article-title":"Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer","volume":"21","author":"Georganaki","year":"2018","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3389\/fphar.2016.00519","article-title":"Anti-angiogenic therapy in cancer: downsides and new pivots for precision medicine","volume":"6","author":"Lupo","year":"2017","journal-title":"Front Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2018.00978","article-title":"Targeting VEGF\/VEGFR to modulate antitumor immunity","volume":"9","author":"Yang","year":"2018","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"154831","DOI":"10.1016\/j.cyto.2019.154831","article-title":"Severe depletion of peripheral blood dendritic cell subsets in obstructive sleep apnea patients: a new link with cancer?","volume":"125","author":"Galati","year":"2020","journal-title":"Cytokine"},{"key":"B11","doi-asserted-by":"publisher","first-page":"E735","DOI":"10.3390\/biom9110735","article-title":"Role of reactive oxygen species in cancer progression: molecular mechanisms and recent advancements","volume":"9","author":"Aggarwal","year":"2019","journal-title":"Biomolecules"},{"key":"B12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fonc.2018.00320","article-title":"Immunomodulation mediated by anti-angiogenic therapy improves CD8 T cell immunity against experimental glioma","volume":"8","author":"Malo","year":"2018","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.humimm.2009.01.014","article-title":"Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions","volume":"70","author":"Mulligan","year":"2009","journal-title":"Hum Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35394","DOI":"10.18632\/oncotarget.26247","article-title":"Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment","volume":"9","author":"Vrecko","year":"2018","journal-title":"Oncotarget"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/s41598-018-37909-5","article-title":"Pancreatic adenocarcinomas with mature blood vessels have better overall survival","volume":"9","author":"Katsuta","year":"2019","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6171","DOI":"10.1158\/0008-5472.CAN-10-0153","article-title":"Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer","volume":"70","author":"Shrimali","year":"2010","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1158\/1078-0432.CCR-12-1626","article-title":"BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice","volume":"19","author":"Liu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1096\/fj.05-4493com","article-title":"Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors","volume":"20","author":"Dirkx","year":"2006","journal-title":"FASEB J"},{"key":"B21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s00262-004-0500-5","article-title":"Angiopoietin decoy secreted at tumor site impairs tumor growth and metastases by inducing local inflammation and altering neoangiogenesis","volume":"53","author":"Melani","year":"2004","journal-title":"Cancer Immunol Immunother"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1158\/1078-0432.CCR-07-0409","article-title":"Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses","volume":"13","author":"Fricke","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3389\/fonc.2014.00061","article-title":"Control of the adaptive immune response by tumor vasculature","volume":"4","author":"Mauge","year":"2014","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1038\/jid.2012.190","article-title":"Nitric oxide-producing myeloid-derived suppressor cells inhibit vascular E-selectin expression in human squamous cell carcinomas","volume":"132","author":"Gehad","year":"2012","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-11-1301","article-title":"Egfl7 promotes tumor escape from immunity by repressing endothelial cell activation","volume":"71","author":"Delfortrie","year":"2011","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"437576","DOI":"10.1155\/2013\/437576","article-title":"Fractalkine (CX3CL1) and its receptor CX3CR1 may contribute to increased angiogenesis in diabetic placenta","volume":"2013","author":"Szukiewicz","year":"2013","journal-title":"Mediators Inflamm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s00109-015-1376-x","article-title":"Immunosuppressive cells in tumor immune escape and metastasis","volume":"94","author":"Liu","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","article-title":"The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer","volume":"52","author":"Missiaen","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.smim.2018.02.002","article-title":"The dark side of tumor-associated endothelial cells","volume":"35","author":"De Sanctis","year":"2018","journal-title":"Semin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/ncb3015","article-title":"The tumor-induced systemic environment as a critical regulator of cancer progression and metastasis","volume":"16","author":"McAllister","year":"2014","journal-title":"Nat Cell Biol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1172\/JCI80005","article-title":"Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected","volume":"125","author":"Marvel","year":"2015","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumor vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.4049\/jimmunol.1400084","article-title":"The Raf kinase inhibitor sorafenib inhibits JAK-STAT signal transduction in human immune cells","volume":"195","author":"Martin del Campo","year":"2015","journal-title":"J Immunol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s00395-012-0310-4","article-title":"Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis","volume":"108","author":"Kanzler","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e7669","DOI":"10.1371\/journal.pone.0007669","article-title":"Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer","volume":"4","author":"Roland","year":"2009","journal-title":"PLoS ONE"},{"key":"B39","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/blood-2007-01-065714","article-title":"Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF","volume":"110","author":"Huang","year":"2007","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune-vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","article-title":"Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells","volume":"16","author":"Carretero","year":"2015","journal-title":"Nat Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1002\/ijc.32829","article-title":"CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils","volume":"146","author":"Zheng","year":"2020","journal-title":"Int J Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/nrc3581","article-title":"History of myeloid-derived suppressor cells","volume":"13","author":"Talmadge","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.18632\/oncotarget.2110","article-title":"Macrophages are recruited to hypoxic tumor areas and acquire a pro-angiogenic M2-polarized phenotype via hypoxic cancer cell derived cytokines Oncostatin M and Eotaxin","volume":"5","author":"Tripathi","year":"2014","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"van Beijnum","year":"2015","journal-title":"Pharmacol Rev"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-08-1954","article-title":"Characterization and regulation of bv8 in human blood cells","volume":"15","author":"Zhong","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","article-title":"Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy?","volume":"20","author":"Ramjiawan","year":"2017","journal-title":"Angiogenesis"},{"key":"B51","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy","volume":"11","author":"Rivera","year":"2015","journal-title":"Cell Rep"},{"key":"B53","doi-asserted-by":"publisher","first-page":"18632","DOI":"10.1073\/pnas.1318415110","article-title":"Combining two strategies to improve perfusion and drug delivery in solid tumors","volume":"110","author":"Stylianopoulosa","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.lungcan.2018.08.019","article-title":"Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: phase 1 cohorts from the KEYNOTE-021 study","volume":"125","author":"Gadgeel","year":"2018","journal-title":"Lung Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijrobp.2014.08.206","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab for NSCLC previously treated with chemotherapy","volume":"90","author":"Rizvi","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B57","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/annonc\/mdx091.010","article-title":"Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): efficacy and safety data","volume":"28","author":"Herbst","year":"2017","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jtho.2019.08.269","article-title":"Efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non-small cell lung cancer (NSCLC)","volume":"14","author":"Han","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","article-title":"Anti-PD-1 antibody SHR-1210 Combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1200\/JCO.2018.36.15_suppl.4074","article-title":"Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC)","volume":"36","author":"Stein","year":"2018","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng","year":"2019","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1200\/JCO.2020.38.15_suppl.4519","article-title":"A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)","volume":"38","author":"Zhu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2017.35.4_suppl.102","article-title":"Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)","volume":"35","author":"Chau","year":"2017","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1200\/JCO.2018.36.4_suppl.92","article-title":"Interim safety and clinical activity in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma from a multicohort phase I study of ramucirumab (R) plus durvalumab (D)","volume":"36","author":"Bang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1200\/JCO.2020.38.15_suppl.4019","article-title":"REGOMUNE: a phase II study of regorafenib plus avelumab in solid tumors\u2014Results of the non-MSI-H metastatic colorectal cancer (mCRC) cohort","volume":"38","author":"Cousin","year":"2020","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1200\/JCO.2017.77.1485","article-title":"Phase II study of two weeks on, one week off sunitinib scheduling in patients with metastatic renal cell carcinoma","volume":"36","author":"Jonasch","year":"2018","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/cas.14294","article-title":"Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101","volume":"111","author":"Uemura","year":"2019","journal-title":"Cancer Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1200\/JCO.2018.36.15_suppl.4560","article-title":"Lenvatinib plus pembrolizumab in patients with renal cell carcinoma: updated results","volume":"36","author":"Lee","year":"2018","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s40425-018-0420-0","article-title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","volume":"6","author":"Amin","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Makker","year":"2019","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1200\/JCO.2004.09.046","article-title":"A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer","volume":"22","author":"Goldberg","year":"2004","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S1470-2045(13)70154-2","article-title":"Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (avex): an open-label, randomised phase 3 trial","volume":"14","author":"Cunningham","year":"2013","journal-title":"Lancet Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.clcc.2019.07.003","article-title":"ACORN: Observational study of bevacizumab in combination with first-line chemotherapy for treatment of metastatic colorectal cancer in the UK","volume":"18","author":"Khakoo","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.clcc.2013.04.006","article-title":"FOLFIRI\u2013bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials","volume":"12","author":"Petrelli","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/1471-2407-12-89","article-title":"Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups","volume":"12","author":"Macedo","year":"2012","journal-title":"BMC Cancer"},{"key":"B82","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2011.38.9650","article-title":"Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer","volume":"30","author":"Meyerhardt","year":"2012","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1200\/JCO.2011.40.7031","article-title":"Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?","volume":"30","author":"Hurwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, Phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/978-3-319-24223-1_5","article-title":"Anti-angiogenesis in personalized therapy of lung cancer","volume":"893","author":"Ellis","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12032-014-0473-y","article-title":"Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis","volume":"32","author":"Sun","year":"2015","journal-title":"Med Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","article-title":"PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer","volume":"31","author":"Patel","year":"2013","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cllc.2014.12.002","article-title":"Cisplatin\/pemetrexed followed by maintenance pemetrexed versus carboplatin\/paclitaxel\/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III randomized trial","volume":"16","author":"Galetta","year":"2015","journal-title":"Clin Lung Cancer"},{"key":"B91","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1200\/JCO.2007.13.1144","article-title":"Outcomes for elderly, advanced-stage non-small cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern cooperative oncology group trial 4599","volume":"26","author":"Ramalingam","year":"2008","journal-title":"J Clin Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/JTO.0b013e3182370e02","article-title":"Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390)","volume":"7","author":"Laskin","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/COC.0000000000000163","article-title":"Isolating the role of bevacizumab in elderly patients with previously untreated nonsquamous non-small-cell lung cancer: secondary analyses of the ECOG 4599 and PointBreak trials","volume":"39","author":"Langer","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1097\/COC.0000000000000644","article-title":"Sequencing ipilimumab immunotherapy before or after chemotherapy (nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF wild-type) metastatic malignant melanoma: Results of a study of Academic and Community Cancer Research United (ACCRU) RU261206I","volume":"43","author":"Markovic","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1200\/JCO.2016.71.1184","article-title":"A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"35","author":"Ornstein","year":"2017","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.juro.2017.09.134","article-title":"Re: A phase II study of intermittent sunitinib in previously untreated patients with metastatic renal cell carcinoma","volume":"199","author":"Laguna","year":"2018","journal-title":"J Urol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/jco.2016.34.2_suppl.559","article-title":"Phase Ib study of pembrolizumab in combination with bevacizumab for the treatment of metastatic renal cell carcinoma: big ten cancer research consortium BTCRC-GU14-003","volume":"34","author":"Dudek","year":"2016","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"CT083","DOI":"10.1158\/1538-7445.AM2017-CT083","article-title":"Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma","volume":"77","author":"Jianjun","year":"2017","journal-title":"Cancer Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11864-019-0617-6","article-title":"The role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer","volume":"20","author":"Perdrizet","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1200\/JCO.2020.38.15_suppl.4585","article-title":"Clinical value of atezolizumab + bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): a network meta-analysis","volume":"38","author":"Vogel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.clon.2016.04.042","article-title":"Ipilimumab and bevacizumab in glioblastoma","volume":"28","author":"Carter","year":"2016","journal-title":"Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"LBA38","DOI":"10.1093\/annonc\/mdw435.34","article-title":"Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)","volume":"27","author":"Herbst","year":"2016","journal-title":"Ann Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1200\/JCO.2017.35.6_suppl.349","article-title":"A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): interim safety and clinical activity in patients with urothelial carcinoma","volume":"35","author":"Petrylak","year":"2017","journal-title":"J Clin Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.19.01598","article-title":"Phase IB\/II trial of lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma, endometrial cancer, and other selected advanced solid tumors","volume":"38","author":"Taylor","year":"2020","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial","volume":"14","author":"Hutson","year":"2013","journal-title":"Lancet Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/14712598.2018.1513485","article-title":"Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma","volume":"18","author":"Gao","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"B110","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1200\/JCO.2020.38.15_suppl.5001","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426","volume":"38","author":"Plimack","year":"2020","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e16627","DOI":"10.1200\/JCO.2020.38.15_suppl.e16627","article-title":"Real-world experience of pembrolizumab plus lenvatinib in unresectable hepatocellular carcinoma in Taiwan","volume":"38","author":"Wu","year":"2020","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1200\/JCO.19.00210","article-title":"Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial","volume":"37","author":"Sheng","year":"2019","journal-title":"J Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"10007","DOI":"10.1200\/JCO.2020.38.15_suppl.10007","article-title":"Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma","volume":"38","author":"Sheng","year":"2020","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"6083","DOI":"10.1200\/JCO.2020.38.15_suppl.6083","article-title":"Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced\/recurrent endometrial cancer (EC)","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2019.37.15_suppl.2522","article-title":"Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose \u2013finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)","volume":"30","author":"Fukuoka","year":"2019","journal-title":"J Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1200\/JCO.2020.38.15_suppl.4028","article-title":"Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China","volume":"38","author":"Gou","year":"2020","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-018-0113-x","article-title":"Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma","volume":"7","author":"Poddubskaya","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/nrc2505","article-title":"VEGF-A splicing: the key to anti-angiogenic therapeutics?","volume":"8","author":"Harper","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/1078-0432.CCR-12-2535","article-title":"Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab","volume":"19","author":"Hegde","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1200\/JCO.2007.15.5655","article-title":"Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma","volume":"26","author":"Hahn","year":"2008","journal-title":"J Clin Oncol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.biochi.2013.03.002","article-title":"Mechanisms of resistance to anti-angiogenesis therapies","volume":"95","author":"Giuliano","year":"2013","journal-title":"Biochimie"},{"key":"B126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-017-0521-0","article-title":"Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study","volume":"10","author":"Liu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-017-0545-5","article-title":"Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3841","DOI":"10.1158\/1078-0432.CCR-10-2806","article-title":"Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors","volume":"17","author":"Rini","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B132","doi-asserted-by":"publisher","first-page":"aar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B133","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12929-019-0588-8","article-title":"Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway","volume":"26","author":"Wakabayashi","year":"2019","journal-title":"J Biomed Sci"},{"key":"B134","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00262-014-1545-8","article-title":"Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma","volume":"63","author":"Simeone","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B135","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-014-1528-9","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.3389\/fimmu.2018.01474","article-title":"Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond","volume":"9","author":"Buder-Bakhaya","year":"2018","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B138","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13073-019-0684-0","article-title":"Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response","volume":"11","author":"Mardis","year":"2019","journal-title":"Genome Med"},{"key":"B139","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"B140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"B141","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/gcc.22365","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival","volume":"55","author":"Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"B142","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1007\/s00259-019-04348-x","article-title":"F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumor expression and response to PD-1 blockade in non-small-cell lung cancer","volume":"46","author":"Jreige","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.2214\/AJR.18.19796","article-title":"Tumor heterogeneity on FDG PET\/CT and immunotherapy: an imaging biomarker for predicting treatment response in patients with metastatic melanoma","volume":"212","author":"Sanli","year":"2019","journal-title":"Am J Roentgenol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","article-title":"The complexity of translating anti-angiogenesis therapy from basic science to the clinic","volume":"37","author":"Ye","year":"2016","journal-title":"Dev Cell"},{"key":"B146","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/annonc\/mdy424.037","article-title":"Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)","volume":"29","author":"Rini","year":"2018","journal-title":"Ann Oncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"612","DOI":"10.21037\/tcr.2019.06.21","article-title":"Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study","volume":"8","author":"Rebuzzi","year":"2019","journal-title":"Transl Cancer Res"},{"key":"B149","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B150","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2326-6066.CIR-16-0084","article-title":"VEGF neutralization plus CTLA-4 blockade alters soluble and cellular factors associated with enhancing lymphocyte infiltration and humoral recognition in melanoma","volume":"4","author":"Wu","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B153","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS ONE"},{"key":"B155","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade:response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-019-02431-8","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"Shibaki","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B157","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.cllc.2019.09.005","article-title":"Extensive-stage small-cell lung cancer with sustained complete response to single-agent nivolumab and immune-related dermatitis","volume":"21","author":"Widick","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B158","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1097\/CCO.0000000000000391","article-title":"Immunotherapy-based combinations: current status and perspectives","volume":"29","author":"de","year":"2017","journal-title":"Curr Opin Oncol."},{"key":"B159","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1200\/jco.2014.32.15_suppl.5010","article-title":"Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC)","volume":"32","author":"Amin","year":"2014","journal-title":"J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3171\/2016.8.PEDS16326","article-title":"Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report","volume":"19","author":"Zhu","year":"2017","journal-title":"J Neurosurg Pediatr"},{"key":"B161","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00234-016-1769-8","article-title":"Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma","volume":"59","author":"Qin","year":"2017","journal-title":"Neuroradiology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2008.19.9356","article-title":"Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice","volume":"27","author":"Kamoun","year":"2009","journal-title":"J Clin Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"B164","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"B165","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.nephro.2017.01.023","article-title":"Thrombotic microangiopathy and cancer","volume":"13","author":"Kheder","year":"2017","journal-title":"Nephrol Ther"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1177\/1078155218774895","article-title":"Bevacizumab-induced atypical hemolytic uremic syndrome and treatment with eculizumab","volume":"25","author":"Vakiti","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"B167","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:31:14Z","timestamp":1598315474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":167,"alternative-id":["10.3389\/fimmu.2020.01956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"article-number":"1956"}}